Study Information

Alliance Study ID: CALGB 40603

NCT Study ID (ClinicalTrials.gov): NCT00861705

Alliance Committee: Breast Cancer

Disease or Cancer Type: Breast Cancer

Alliance Study Chair: William M Sikov

Status: COMPLETED


Study Description

This randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Related Publications

For publications related to this and other clinical trials, visit the Alliance Publications Application.

Data Sources & Contacts

Related Alliance Trials

Related News